304 related articles for article (PubMed ID: 36088954)
1. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
Alexander JL; Kennedy NA; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Liu Z; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Goodhand JR; Hart AL; Lees CW; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):342-352. PubMed ID: 35123676
[TBL] [Abstract][Full Text] [Related]
3. Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
Liu Z; Alexander JL; Le K; Zhou X; Ibraheim H; Anandabaskaran S; Saifuddin A; Lin KW; McFarlane LR; Constable L; Seoane RC; Anand N; Bewshea C; Nice R; D'Mello A; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HR; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Hart AL; Lees CW; Goodhand JR; Kennedy NA; Pollock KM; Ahmad T; Powell N;
EClinicalMedicine; 2023 Oct; 64():102249. PubMed ID: 37842172
[TBL] [Abstract][Full Text] [Related]
4. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043
[TBL] [Abstract][Full Text] [Related]
5. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
Kennedy NA; Janjua M; Chanchlani N; Lin S; Bewshea C; Nice R; McDonald TJ; Auckland C; Harries LW; Davies M; Michell S; Kok KB; Lamb CA; Smith PJ; Hart AL; Pollok RC; Lees CW; Boyton RJ; Altmann DM; Sebastian S; Powell N; Goodhand JR; Ahmad T
Gut; 2023 Feb; 72(2):295-305. PubMed ID: 35902214
[TBL] [Abstract][Full Text] [Related]
6. Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib.
Liu Z; Alexander JL; Yee Eng K; Ibraheim H; Anandabaskaran S; Saifuddin A; Constable L; Castro Seoane R; Bewshea C; Nice R; D'Mello A; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Hart AL; Lees CW; Goodhand JR; Kennedy NA; Pollock KM; Ahmad T; Powell N
J Crohns Colitis; 2024 Apr; 18(4):560-569. PubMed ID: 37941436
[TBL] [Abstract][Full Text] [Related]
7. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
[TBL] [Abstract][Full Text] [Related]
8. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S
Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899
[TBL] [Abstract][Full Text] [Related]
9. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
[TBL] [Abstract][Full Text] [Related]
10. Response to COVID-19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose.
Shiga H; Kakuta Y; An K; Abe Y; Fujimaki S; Shimoyama Y; Naito T; Moroi R; Kuroha M; Khor SS; Kawai Y; Tokunaga K; Kinouchi Y; Masamune A
J Gastroenterol Hepatol; 2023 Jan; 38(1):44-51. PubMed ID: 36066279
[TBL] [Abstract][Full Text] [Related]
11. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC
Front Immunol; 2022; 13():920333. PubMed ID: 35865529
[TBL] [Abstract][Full Text] [Related]
12. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Lin S; Kennedy NA; Saifuddin A; Sandoval DM; Reynolds CJ; Seoane RC; Kottoor SH; Pieper FP; Lin KM; Butler DK; Chanchlani N; Nice R; Chee D; Bewshea C; Janjua M; McDonald TJ; Sebastian S; Alexander JL; Constable L; Lee JC; Murray CD; Hart AL; Irving PM; Jones GR; Kok KB; Lamb CA; Lees CW; Altmann DM; Boyton RJ; Goodhand JR; Powell N; Ahmad T;
Nat Commun; 2022 Mar; 13(1):1379. PubMed ID: 35296643
[TBL] [Abstract][Full Text] [Related]
13. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
14. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.
Zacharopoulou E; Orfanoudaki E; Tzouvala M; Tribonias G; Kokkotis G; Kitsou V; Almpani F; Christidou A; Viazis N; Mantzaris GJ; Tsafaridou M; Karmiris K; Theodoropoulou A; Papathanasiou E; Zampeli E; Michopoulos S; Tigkas S; Michalopoulos G; Laoudi E; Karatzas P; Mylonas I; Kyriakos N; Liatsos C; Kafetzi T; Theocharis G; Taka S; Panagiotopoulou K; Koutroubakis IE; Bamias G
Inflamm Bowel Dis; 2023 Feb; 29(2):228-237. PubMed ID: 35394529
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
Jørgensen KK; Høivik ML; Chopra A; Benth JŠ; Ricanek P; Moum PB; Jyssum I; Bolstad N; Warren DJ; Vaage PJT; Munthe PLA; Lundin PKEA; Anisdahl K; Syversen SW; Goll GL; Lund-Johansen F; Medhus AW; Jahnsen PJ
Scand J Gastroenterol; 2023; 58(8):874-882. PubMed ID: 36788656
[TBL] [Abstract][Full Text] [Related]
16. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
[TBL] [Abstract][Full Text] [Related]
17. Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects.
Vollenberg R; Lorentzen EU; Kühn J; Nowacki TM; Meier JA; Trebicka J; Tepasse PR
Vaccines (Basel); 2023 Aug; 11(9):. PubMed ID: 37766088
[TBL] [Abstract][Full Text] [Related]
18. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Abhishek A; Boyton RJ; Peckham N; McKnight Á; Coates LC; Bluett J; Barber V; Cureton L; Francis A; Appelbe D; Eldridge L; Julier P; Valdes AM; Brooks T; Rombach I; Altmann DM; Nguyen-Van-Tam JS; Williams HC; Cook JA;
Lancet Respir Med; 2022 Sep; 10(9):840-850. PubMed ID: 35772416
[TBL] [Abstract][Full Text] [Related]
19. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
[TBL] [Abstract][Full Text] [Related]
20. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
